4.7 Article

A Prodromal Brain-Clinical Pattern of Cognition in Synucleinopathies

期刊

ANNALS OF NEUROLOGY
卷 89, 期 2, 页码 341-357

出版社

WILEY
DOI: 10.1002/ana.25962

关键词

-

资金

  1. Canadian Institutes of Health Research (CIHR)
  2. Fonds de recherche du Quebec - Sante (FRQ-S)
  3. W. Garfield Weston Foundation
  4. NHMRC Dementia Team Grant [1095127]
  5. Appel a Projet Interne (API) of the University Hospital of Strasbourg
  6. Alsace Alzheimer 67
  7. Fondation Universite de Strasbourg
  8. Ag2R la Mondiale
  9. Projet Hospitalier de Recherche Clinique (PHRC) inter-regional in Strasbourg
  10. National Health and Medical Research Council of Australia [1095127] Funding Source: NHMRC

向作者/读者索取更多资源

A brain-clinical signature was identified in patients with iRBD that can predict conversion to more severe forms of synucleinopathy, particularly DLB. This signature may serve as a new biomarker to optimize patient care and administer neuroprotective trials.
Objective Isolated (or idiopathic) rapid eye movement sleep behavior disorder (iRBD) is associated with dementia with Lewy bodies (DLB) and Parkinson's disease (PD). Biomarkers are lacking to predict conversion to a dementia or a motor-first phenotype. Here, we aimed at identifying a brain-clinical signature that predicts dementia in iRBD. Methods A brain-clinical signature was identified in 48 patients with polysomnography-confirmed iRBD using partial least squares between brain deformation and 27 clinical variables. The resulting variable was applied to 78 patients with iRBD followed longitudinally to predict conversion to a synucleinopathy, specifically DLB. The deformation scores from patients with iRBD were compared with 207 patients with PD, DLB, or prodromal DLB to assess if scores were higher in DLB compared to PD. Results One latent variable explained 31% of the brain-clinical covariance in iRBD, combining cortical and subcortical deformation and subarachnoid/ventricular expansion to cognitive and motor variables. The deformation score of this signature predicted conversion to a synucleinopathy in iRBD (p = 0.036, odds ratio [OR] = 2.249; 95% confidence interval [CI] = 1.053-4.803), specifically to DLB (OR = 4.754; 95% CI = 1.283-17.618, p = 0.020) and not PD (p = 0.286). Patients with iRBD who developed dementia had scores similar to clinical and prodromal patients with DLB but higher scores compared with patients with PD. The deformation score also predicted cognitive performance over 1, 2, and 4 years in patients with PD. Interpretation We identified a brain-clinical signature that predicts conversion in iRBD to more severe/dementing forms of synucleinopathy. This pattern may serve as a new biomarker to optimize patient care, target risk reduction strategies, and administer neuroprotective trials. ANN NEUROL 2020

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据